PROTEASE-RESISTANT INSULIN ANALOGUES Russian patent published in 2014 - IPC C07K14/62 C12N15/17 A61K38/28 A61P5/50 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biotechnology, namely to novel analogues of insulin and can be used in medicine. An insulin analogue, in which at least two hydrophobic amino acids are replaced with hydrophilic amino acids in comparison with a parent insulin, and where A-chain of the insulin analogue contains at least one mutation and B-chain contains at least one mutation in comparison with the parent insulin, and at least one mutation in A-chain is in one or more cleavage sites, selected from the group, consisting of A13-14, A14-15 and A19-20, and at least one mutation in B-chain is in one or more cleavage sites, selected from the group, consisting of B2-3, B6-7, B9-10, B10-11, B13-14, B14-15, B16-17, B22-23, B24-25, B25-26, and where amino acid in B30 position is deleted. The insulin analogue is used as a component of a pharmaceutical composition for treatment or prevention of hyperglycemia, type 1 or type 2 diabetes mellitus.

EFFECT: invention makes it possible to obtain the insulin analogue with an increased resistance with respect to one or more proteolytic enzymes in comparison with the parent insulin.

44 cl, 4 dwg, 5 tbl, 11 ex